4s3, With $20M in Tow, Pursues Route for Delivering Drugs to Muscle
Summary
4s3, With $20M in Tow, Pursues Route for Delivering Drugs to Muscle Xconomy Boston — If you ask 4s3 Bioscience CEO Timothy Harris what the name of his Medford, MA startup signifies, you won’t get much of an enthusiastic response.“We believe this is a platform technology that can be applied to a number of different muscle diseases.” 4s3’s development plan got a big boost on March 5, when the company announced it had closed a $20 million Series A financing with KLP Enterprises.KLP is a trust formed by Karen Pritzker—a member of the famed Pritzker family, creators of the Hyatt hotel chain—and her husband, investor Michael Vlock.Harris co-founded 4s3 in 2007 with Dustin Armstrong, who serves as vice president of research, and built it on an antibody-delivery technology they licensed from the University of California in Los Angeles.4s3’s lead programs target myotubular myopathy and myotonic dystrophy, both of which are rare, genetic diseases that result in abnormal coding for proteins that are essential for muscular function.
Classifications
AskAI Classifications
LabelsLinked Companies
